GlassScriptPhysician profile
Michael G Desautel
NPI 1831161660
$11,823.43
in general payments reported to CMS, 2019-2025
26 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,712 · 2020: $3,755 · 2021: $3,426 · 2022: $381 · 2023: $140 · 2024: $101 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laser Specialty Medical, LLC | $9,500.00 | 2019-2021 | |
| Astellas Pharma US INC | $617.47 | 2019-2022 | |
| Medtronic, INC. | $372.87 | 2021-2025 | Interstim, Nuro |
| Boston Scientific Corporation | $249.34 | 2019-2025 | Spaceoar Vue System - 10ml |
| Teleflex LLC | $169.53 | 2021-2025 | Barrigel |
| Medtronic USA, INC. | $161.37 | 2019-2020 | |
| Axonics, INC. | $150.11 | 2023-2024 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $88.02 | 2019-2021 | |
| Pfizer INC. | $75.49 | 2019-2020 | |
| Cook Medical LLC | $72.18 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $50.92 | 2019-2025 | Adstiladrin |
| Procept Biorobotics Corporation | $47.27 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $40.41 | 2019-2020 | |
| Rochester Medical Corporation | $40.35 | 2019-2020 | |
| Olympus America INC. | $30.70 | 2023 | Itind System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $22.57 | 2020 | |
| Neotract INC. | $21.39 | 2019 | |
| Coloplast Corp | $18.53 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.77 | 2020 | |
| Dendreon Pharmaceuticals LLC | $17.39 | 2020 | |
| Dentsply Ih INC. | $16.79 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.27 | 2019 | |
| Myriad Genetic Laboratories, INC. | $15.18 | 2022 | |
| Allergan, INC. | $11.51 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$136,647.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Desautel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.